Prof Leon AaronsBSc, MSc, PhD

Professor

Full contact details
View graph of relations

Publications

  1. Published

    Methodological approaches to the population analysis of toxicity data

    Aarons, L. & Graham, G., 31 Mar 2001, In : Toxicology Letters. 120, 1-3, p. 405-410 5 p.

    Research output: Contribution to journalArticle

  2. Published

    Pharmacodynamics of controlled release verapamil in patients with hypertension: An analysis using spline functions

    Aarons, L., Baxter, C. & Gupta, S., Jul 2004, In : Biopharmaceutics and Drug Disposition. 25, 5, p. 219-225 6 p.

    Research output: Contribution to journalArticle

  3. Published

    Editorial: Pharmacokinetic and pharmacodynamic modelling in drug development

    Aarons, L., Jun 1999, In : Statistical Methods in Medical Research. 8, 3, p. 181-182

    Research output: Contribution to journalArticle

  4. Published

    COST B15: modelling in drug development

    Aarons, L., Balant, L. & Boobis, A., Jul 2001, In : British Journal of Clinical Pharmacology. 52, 1, p. 118-119

    Research output: Contribution to journalArticle

  5. Published

    Optimal design of pharmacokinetic studies

    Aarons, L. & Ogungbenro, K., Mar 2010, In : Basic and Clinical Pharmacology and Toxicology. 106, 3, p. 250-255 5 p.

    Research output: Contribution to journalArticle

  6. Published

    Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients

    Aarons, L., Ahmed, I. A. & Deleu, D., Jan 2005, In : Archives of Medical Research. 36, 1, p. 49-53 4 p.

    Research output: Contribution to journalArticle

  7. Published

    Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children

    Aarons, L., Rowland, M., Khan, A., Taborelli, G., Ferrea, G., Tarantino, V., Fioredda, F., Rosina-Parenti, R., Cavenaghi, L. & Borgonovi, M., 1 Oct 1998, In : European Journal of Pharmaceutical Sciences. 6, 4, p. 265-270 5 p.

    Research output: Contribution to journalArticle

  8. Published

    Role of modelling and simulation in Phase I drug development

    Aarons, L., Karlsson, M. O., Mentre, F., Rombout, F., Steimer, J. L. & Van Peer, A., 2001, In : European Journal of Pharmaceutical Sciences. 13, 2, p. 115-122 7 p.

    Research output: Contribution to journalArticle

  9. Published

    Software for population pharmacokinetics and pharmacodynamics

    Aarons, L., 1999, In : Clinical Pharmacokinetics. 36, 4, p. 255-264 9 p.

    Research output: Contribution to journalArticle

  10. Published

    "Population modelling". In: Variability in Human Drug Response. Proceedings of the Esteve Foundation Symposium VIII.

    Aarons, L., 1999, In : Excerpta Medica, Amsterdam.

    Research output: Contribution to journalArticle

  11. Published

    Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies

    Aarons, L., Rowland, M., Balant, L. P., Mentré, F., Morselli, P. L., Steimer, J. L. & Vozeh, S., Jan 1996, European Journal of Clinical Pharmacology|Eur J Clin Pharmacol. Springer Nature, Vol. 49. p. 251-254 3 p.

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

  12. Published

    Mixed effects modelling of toxicokinetic data

    Aarons, L., 2002, In : The Toxicologist. 66 (1-S)

    Research output: Contribution to journalArticle

  13. Published

    The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, Commission of the European Community, Luxembourg

    Aarons, L., Rowland, M., Balant, L. P., Danhof, M., Gex-Fabry, M., Gundert-Remy, U. A., Karlsson, M. O., Mentre, F., Morselli, P. L., Rombout, F., Steimer, J. L. & Vozeh, S., 1997, No publisher name. (proceedings of a meeting, edited by authors and published as a book)

    Research output: Book/ReportAnthology

  14. Published

    Population pharmacokinetic analysis of ropivacaine and its metabolite 2′,6′-pipecoloxylidide from pooled data in neonates, infants, and children

    Aarons, L., Sadler, B., Pitsiu, M., Sjövall, J., Henriksson, J. & Molnár, V., Sep 2011, In : British Journal of Anaesthesia. 107, 3, p. 409-424 15 p.

    Research output: Contribution to journalArticle

  15. Published

    Population approaches/sparse data analysis for human variability in kinetics and dynamics

    Aarons, L., 15 Oct 1996, In : Environmental Toxicology and Pharmacology. 2, 2-3, p. 197-199 2 p.

    Research output: Contribution to journalArticle

  16. Published

    An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine

    Adams, N. D., Godfrey, K. R., Chapman, M. J., Chappell, M. J., Aarons, L. & Duffull, S. B., 2001, In : Journal of pharmacokinetics and pharmacodynamics. 28, 1, p. 93-105 12 p.

    Research output: Contribution to journalArticle

  17. Published

    Critical Analysis and Communication: an alternative to the final year project

    Barber, J., Demonacos, C., Aarons, L., Steinke, D. & Tully, M., 30 Jun 2014, host publication.

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

  18. Published

    Quantitative structure-pharmacokinetic relationships. I. Development of a whole body physiologically based model to characterise changes in pharmacokinetics across a homologous series of barbiturates in the rat.

    Blakey, G. M., Al, N. I., Arundel, P. A., Aarons, L. & Rowland, M., 1997, In : J. Pharmaco. Biopharm.. 25 (3)

    Research output: Contribution to journalArticle

  19. Published

    A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

    Callies, S., De Alwis, D. P., Wright, J. G., Sandler, A., Burgess, M. & Aarons, L., 1 Feb 2003, In : Cancer Chemotherapy and Pharmacology. 51, 2, p. 107-118 11 p.

    Research output: Contribution to journalArticle

  20. Published

    Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCI (LY335979)

    Callies, S., De Alwis, D. P., Mehta, A., Burgess, M. & Aarons, L., Jul 2004, In : Cancer Chemotherapy and Pharmacology. 54, 1, p. 39-48 9 p.

    Research output: Contribution to journalArticle

  21. Published

    A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)

    Callies, S., De Alwis, D. P., Harris, A., Vasey, P., Beijnen, J. H., Schellens, J. H., Burgess, M. & Aarons, L., 1 Jul 2003, In : British Journal of Clinical Pharmacology. 56, 1, p. 46-56 10 p.

    Research output: Contribution to journalArticle

  22. Published
  23. Published

    Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: Application to midazolam and a phase i compound. Part 2: Clinical trial results

    Chenel, M., Bouzom, F., Cazade, F., Ogungbenro, K., Aarons, L. & Mentré, F., Dec 2008, In : Journal of pharmacokinetics and pharmacodynamics. 35, 6, p. 661-681 20 p.

    Research output: Contribution to journalArticle

  24. Published

    Optimal blood sampling time windows for parameter estimation using a population approach: Design of a phase II clinical trial

    Chenel, M., Ogungbenro, K., Duval, V., Laveille, C., Jochemsen, R. & Aarons, L., Dec 2005, In : Journal of pharmacokinetics and pharmacodynamics. 32, 5-6, p. 737-756 19 p.

    Research output: Contribution to journalArticle

  25. Published

    The design and analysis of parallel experiments to produce structurally identifiable models

    Cheung, S. Y. A., Yates, J. W. T. & Aarons, L., Feb 2013, In : Journal of pharmacokinetics and pharmacodynamics. 40, 1, p. 93-100 7 p.

    Research output: Contribution to journalArticle

  26. Published

    Structural identifiability analysis and reparameterisation (parameter reduction) of a cardiovascular feedback model

    Cheung, S. Y. A., Majid, O., Yates, J. W. T. & Aarons, L., 16 Jul 2012, In : European Journal of Pharmaceutical Sciences. 46, 4, p. 259-271 12 p.

    Research output: Contribution to journalArticle

  27. Published

    Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose

    Cheung, S. Y. A. ., Rodgers, T., Aarons, L., Gueorguieva, I., Dickinson, G. L., Murby, S., Brown, C., Collins, B. & Rowland, M., 22 Dec 2017, In : British Journal of Pharmacology . p. 1 17 p.

    Research output: Contribution to journalArticle

  28. Published

    Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination

    Chou, C. H., Aarons, L. & Rowland, M., 1998, In : Journal of pharmacokinetics and biopharmaceutics. 26, 5, p. 595-615 20 p.

    Research output: Contribution to journalArticle

  29. Published

    Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates

    Cressey, T. R., Punyawudho, B., Le Coeur, S., Jourdain, G., Saenjum, C., Capparelli, E. V., Jittayanun, K., Phanomcheong, S., Luvira, A., Borkird, T., Puangsombat, A., Aarons, L., Sukrakanchana, P. O., Urien, S., Lallemant, M., Sangsawang, S., Achalapong, J., Preedisripipat, K., Putiyanun, C., Wanchaitanawong, V. & 31 others, Yuthavisuthi, P., Ngampiyaskul, C., Kanjanavikai, P., Chotivanich, N., Hongsiriwon, S., Suwankornsakul, W., Sreshthatat, P., Kanjanasing, A., Kwanchaipanich, R., Rawangban, B., Santadusit, S., Jarupanich, T., Warachit, B., Siriwachirachai, T., Rojanakarin, P., Vivatpatanakul, K., Hanpinitsak, S., Wanasiri, P., Srirojana, S., Kongpanichkul, R., Bunjongpak, S., Sabsanong, P., Liampongsabuddhi, P., Pongdetudom, K., Khamja, P., Akarathum, N., Phonin, S. A., Limpitikul, W., Jungpipun, J., Petprakorp, R. & The PHPT-5 study team, 15 Aug 2017, In : Journal of Acquired Immune Deficiency Syndromes. 75, 5, p. 554-560 7 p.

    Research output: Contribution to journalArticle

  30. Published

    Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1

    Danson, S. J., Johnson, P., Ward, T. H., Dawson, M., Denneny, O., Dickinson, G., Aarons, L., Watson, A., Jowle, D., Cummings, J., Robson, L., Halbert, G., Dive, C. & Ranson, M., 2011, In : Annals of Oncology. 22, 7, p. 1653-1660 7 p.

    Research output: Contribution to journalArticle

  31. Published

    IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes

    Darwich, A., Aarons, L., Galetin, A., Rostami-Hochaghan et al, A., Margolskee, A., Pepin, X., Carlert, S., Hammarberg, M., Hilgendorf, C., Johansson, P., Karlsson, E., Murphy, D., Tannergren, C., Thorn, H., Yasin, M., Mazuir, F., Nicolas, O., Ramusovic, S., Xu, C., Pathak, S. & 43 others, Korjamo, T., Laru, J., Malkki, J., Pappinen, S., Tuunainen, J., Dressman, J., Hansmann, S., Kostewicz, E. S., He, H., Heimbach, T., Wu, F., Hoft, C., Pang, Y., Bolger, M., Huehn, E., Heimbach, T., Wu, F., Hoft, C., Pang, Y., Bolger, M. B., Huehn, E., Lukacova, V., Mullin, J. M., Szeto, K. X., Costales, C., Lin, J., McAllister, M., Modi, S., Rotter, C., Varma, M., Wong, M., Mitra, A., Bevernage, J., Biewenga, J., Peer, A. V., Lloyd, R., Shardlow, C., Langguth, P., Mishenzon, I., Nguyen, M. A., Brown, J., Lennerans, H. & Abrahmsson, B., 1 Jan 2017, In : European Journal of Pharmaceutical Sciences. 96, p. 626-642 17 p.

    Research output: Contribution to journalArticle

  32. Published

    Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future

    Darwich, A., Ogungbenro, K., Vinks, A. A., Powell, J. R., Reny, J-L., Marsousi, N., Daali, Y., Fairman, D., Cook, J., Lesko, L. J., McCune, J. S., Knibbe, C. A. J., de Wildt, S. N., Leeder, J. S., Neely, M. N., Zuppa, A. F., Vicini, P., Aarons, L., Johnson, T. N., Boiani, J. & 1 others, Rostami-Hodjegan, A., 2017, In : Clinical Pharmacology & Therapeutics.

    Research output: Contribution to journalArticle

  33. Published

    Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

    Davies, G. R., Brindle, R., Khoo, S. H. & Aarons, L. J., Sep 2006, In : Antimicrobial Agents and Chemotherapy. 50, 9, p. 3154-3156 2 p.

    Research output: Contribution to journalArticle

  34. Published

    Population pharmacokinetics of ondansetron: A covariate analysis

    De Alwis, D. P., Aarons, L. & Palmer, J. L., 1998, In : British Journal of Clinical Pharmacology. 46, 2, p. 117-125 8 p.

    Research output: Contribution to journalArticle

  35. Published

    Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients

    Deleu, D., Aarons, L. & Ahmed, I. A., 2001, In : European journal of clinical pharmacology. 57, 3, p. 243-248 5 p.

    Research output: Contribution to journalArticle

  36. Published

    Study of the phamacokinetic profile of anti-epileptic drugs in an adult Omani epileptic population using NONMEM.

    Deleu, D., Aarons, L. & Ahmed, I. A., 2002, In : EPILEPSIA. 43

    Research output: Contribution to journalArticle

  37. Published

    Critical Analysis and Communication: An Alternative to the Research Project

    Demonacos, C., Aarons, L. & Barber, J., 2014, In : Health & Social Care Education. p. 1-5 4 p.

    Research output: Contribution to journalArticle

  38. Published

    Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals

    Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., Merry, C., Autar, R. S., Burger, D. M. & Aarons, L. J., 2008, In : Journal of Antimicrobial Chemotherapy. 62, 6, p. 1344-1355 11 p.

    Research output: Contribution to journalArticle

  39. Published

    Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing

    Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L. & Back, D. J., Jul 2008, In : Journal of Antimicrobial Chemotherapy. 62, 1, p. 161-167 6 p.

    Research output: Contribution to journalArticle

  40. Published

    Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

    Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., Khoo, S., Pozniak, A. & Aarons, L., 2009, In : Journal of Antimicrobial Chemotherapy. 63, 6, p. 1233-1243 10 p.

    Research output: Contribution to journalArticle

  41. Published

    Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies

    Dickinson, L., Boffito, M., Back, D., Else, L., Von Hentig, N., Davies, G., Khoo, S., Pozniak, A., Moyle, G. & Aarons, L., Jun 2011, In : Antimicrobial Agents and Chemotherapy. 55, 6, p. 2775-2782 7 p.

    Research output: Contribution to journalArticle

  42. Published

    Bayesian optimal designs for pharmacokinetic models: Sensitivity to uncertainty

    Dokoumetzidis, A. & Aarons, L., Sep 2007, In : Journal of Biopharmaceutical Statistics. 17, 5, p. 851-867 16 p.

    Research output: Contribution to journalArticle

  43. Published

    Propagation of population PK and PD information using a Bayesian approach: Dealing with non-exchangeability

    Dokoumetzidis, A. & Aarons, L., Feb 2006, In : Journal of pharmacokinetics and pharmacodynamics. 33, 1, p. 29-48 19 p.

    Research output: Contribution to journalArticle

  44. Published

    Analytical expressions for combining population pharmacokinetic parameters from different studies

    Dokoumetzidis, A. & Aarons, L., Jul 2008, In : Journal of Biopharmaceutical Statistics. 18, 4, p. 662-676 14 p.

    Research output: Contribution to journalArticle

  45. Published

    Propagation of population pharmacokinetic information using a Bayesian approach: Comparison with meta-analysis

    Dokoumetzidis, A. & Aarons, L., Aug 2005, In : Journal of pharmacokinetics and pharmacodynamics. 32, 3-4, p. 401-418 17 p.

    Research output: Contribution to journalArticle

  46. Published

    A pharmacokinetic simulation model for ivabradine in healthy volunteers

    Duffull, S. B., Chabaud, S., Nony, P., Laveille, C., Girard, P. & Aarons, L., Jun 2000, In : European Journal of Pharmaceutical Sciences. 10, 4, p. 285-294 9 p.

    Research output: Contribution to journalArticle

  47. Published

    Computer Assisted Design of Phase II(b) Oral Dose Ranging Trial for Naratriptan - Results of a Pilot Study. Scientific Conference "Pharmacokinetics - UK", Manchester, UK. November 4-6, 1998

    Duffull, S., Nestorov, I. & Aarons, L., 1998, Conference Proceedings.

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

  48. Published

    Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers

    Duffull, S. B. & Aarons, L., Jun 2000, In : European Journal of Pharmaceutical Sciences. 10, 4, p. 275-284 9 p.

    Research output: Contribution to journalArticle

  49. Published

    A pharmacokinetic model for tenidap in normal volunteers and rheumatoid arthritis patients

    Evans, L., Aarons, L. & Coates, P., 1999, In : Pharmaceutical Research. 16, 10, p. 1608-1615 7 p.

    Research output: Contribution to journalArticle

  50. Published

    A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies

    Evans, L., Aarons, L. & Brearley, C., Feb 2005, In : Journal of Pharmacy and Pharmacology. 57, 2, p. 183-189 6 p.

    Research output: Contribution to journalArticle

Previous 1 2 3 4 Next